Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review.

[1]  Anisur Rahman,et al.  Efficacy and Safety of Nonbiologic Immunosuppressants in the Treatment of Nonrenal Systemic Lupus Erythematosus: A Systematic Review , 2013, Arthritis care & research.

[2]  Jiang‐hua Chen,et al.  Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis , 2012, Journal of Zhejiang University SCIENCE B.

[3]  P. Carreira,et al.  Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study , 2012, Lupus.

[4]  P. Emery,et al.  B cell biomarkers of rituximab responses in systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[5]  Fengchun Zhang,et al.  Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study. , 2011, Rheumatology.

[6]  D. Isenberg,et al.  The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. , 2011, Rheumatology.

[7]  C. Prieto,et al.  Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus , 2011, Lupus.

[8]  N. Ortego-Centeno,et al.  Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label , 2011, Arthritis research & therapy.

[9]  C. Gordon,et al.  Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER) , 2011, Lupus.

[10]  Kenneth G. C. Smith,et al.  Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  E. Vignon,et al.  Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. , 2010, Arthritis and rheumatism.

[12]  E. de Ramón,et al.  Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. , 2010, Clinical and experimental rheumatology.

[13]  E. Murray,et al.  Off-label use of rituximab in systemic lupus erythematosus: a systematic review , 2010, Clinical Rheumatology.

[14]  M. García-Carrasco,et al.  Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients , 2010, Lupus.

[15]  D. Isenberg,et al.  Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies. , 2009, Best practice & research. Clinical rheumatology.

[16]  C. Gordon,et al.  Effects of rituximab on resistant SLE disease including lung involvement , 2009, Lupus.

[17]  M. Bokarewa,et al.  Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. , 2008, The Journal of rheumatology.

[18]  D. Isenberg,et al.  A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. , 2008, Arthritis and rheumatism.

[19]  E. L. Prak,et al.  Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus , 2008, Annals of the rheumatic diseases.

[20]  J. Anaya,et al.  Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases? , 2008, Clinical reviews in allergy & immunology.

[21]  L. Klareskog,et al.  Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response , 2007, Annals of the rheumatic diseases.

[22]  Kazuhiko Yamamoto,et al.  A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus , 2007, Modern rheumatology.

[23]  D. Isenberg,et al.  B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response , 2007, Annals of the rheumatic diseases.

[24]  I. Gunnarsson,et al.  Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. , 2007, Arthritis and rheumatism.

[25]  T. Mimori,et al.  Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system , 2006, Annals of the rheumatic diseases.

[26]  Kenneth G. C. Smith,et al.  Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. , 2006, Arthritis and rheumatism.

[27]  R. González-Amaro,et al.  Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study , 2006, Arthritis research & therapy.

[28]  D. Isenberg,et al.  B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. , 2005, Rheumatology.

[29]  P. Sfikakis,et al.  Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. , 2005, Arthritis and rheumatism.

[30]  M. Dougados,et al.  Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases , 2004, Annals of the rheumatic diseases.

[31]  I. Sanz,et al.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. , 2004, Arthritis and rheumatism.

[32]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[33]  C. Gordon,et al.  Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. , 2010, Arthritis and rheumatism.